# HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

> **NCT06632093** · — · RECRUITING · sponsor: **First Hospital of China Medical University** · enrollment: 84 (estimated)

## Conditions studied

- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Hepatic Arterial Infusion Chemotherapy
- Lenvatinib
- PD-1
- Systemic Therapy

## Interventions

- **PROCEDURE:** hepatic artery infusion chemotherapy
- **DRUG:** Lenvatinib + PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06632093
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632093, "HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06632093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*